BACKGROUND: Subclinical hypothyroidism (SCH) is associated with an increased cardiovascular risk, but little information is available about its association with high-sensitivity C-reactive protein (hs-CRP). OBJECTIVES: This study aims to analyze the association between SCH and hs-CRP using baseline data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). METHODS: The study has a cross-sectional design. We included subjects with normal thyroid function (thyroid-stimulating hormone, TSH, 0.4-4.0 μIU/ml and normal free thyroxine, fT4, 10.3-24.45 pmol/l) and SCH (TSH >4.0 μIU/ml and normal fT4) who were evaluated for hs-CRP. We excluded individuals on medications that affect thyroid function and those who had prevalent cardiovascular disease. Multivariate linear regression evaluated hs-CRP and TSH as continuous variables, and logistic regression models assessed hs-CRP ≥19.05 nmol/l as the dependent variable and crescent quintiles of TSH as the independent variables adjusted for demographic and cardiovascular risk factors. RESULTS: We included 12,284 subjects with a median age of 50 years (interquartile range = 45-57); 6,408 (52.2%) were female, 11,589 (94.3%) were euthyroid, and 695 (5.7%) had SCH. Bivariate analyses of participants stratified into quintiles of TSH revealed differences according to hs-CRP but not the Framingham risk score. The fifth quintile of TSH was not associated with elevated hs-CRP, odds ratio = 1.11 (95% confidence interval = 0.98-1.26), p = 0.102, in a fully adjusted logistic model, also consistent with the linear model (β = 0.024, p = 0.145). CONCLUSIONS: TSH is not associated with hs-CRP. Obesity and insulin resistance are very important confounders in the study of the association between SCH and hs-CRP.
BACKGROUND: Subclinical hypothyroidism (SCH) is associated with an increased cardiovascular risk, but little information is available about its association with high-sensitivity C-reactive protein (hs-CRP). OBJECTIVES: This study aims to analyze the association between SCH and hs-CRP using baseline data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). METHODS: The study has a cross-sectional design. We included subjects with normal thyroid function (thyroid-stimulating hormone, TSH, 0.4-4.0 μIU/ml and normal free thyroxine, fT4, 10.3-24.45 pmol/l) and SCH (TSH >4.0 μIU/ml and normal fT4) who were evaluated for hs-CRP. We excluded individuals on medications that affect thyroid function and those who had prevalent cardiovascular disease. Multivariate linear regression evaluated hs-CRP and TSH as continuous variables, and logistic regression models assessed hs-CRP ≥19.05 nmol/l as the dependent variable and crescent quintiles of TSH as the independent variables adjusted for demographic and cardiovascular risk factors. RESULTS: We included 12,284 subjects with a median age of 50 years (interquartile range = 45-57); 6,408 (52.2%) were female, 11,589 (94.3%) were euthyroid, and 695 (5.7%) had SCH. Bivariate analyses of participants stratified into quintiles of TSH revealed differences according to hs-CRP but not the Framingham risk score. The fifth quintile of TSH was not associated with elevated hs-CRP, odds ratio = 1.11 (95% confidence interval = 0.98-1.26), p = 0.102, in a fully adjusted logistic model, also consistent with the linear model (β = 0.024, p = 0.145). CONCLUSIONS: TSH is not associated with hs-CRP. Obesity and insulin resistance are very important confounders in the study of the association between SCH and hs-CRP.
Authors: John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli Journal: Arch Intern Med Date: 2005-11-28
Authors: Sandhi M Barreto; Roberto M Ladeira; Bruce B Duncan; Maria Ines Schmidt; Antonio A Lopes; Isabela M Benseñor; Dora Chor; Rosane H Griep; Pedro G Vidigal; Antonio L Ribeiro; Paulo A Lotufo; José Geraldo Mill Journal: J Epidemiol Community Health Date: 2015-10-28 Impact factor: 3.710
Authors: Robert Park; Robert Detrano; Min Xiang; Paul Fu; Youhanna Ibrahim; Laurie LaBree; Stanley Azen Journal: Circulation Date: 2002-10-15 Impact factor: 29.690
Authors: Jose de Jesus Garduño-Garcia; Ulices Alvirde-Garcia; Guadalupe López-Carrasco; Ma Elena Padilla Mendoza; Roopa Mehta; Olimpia Arellano-Campos; Ricardo Choza; Leobardo Sauque; Maria Eugenia Garay-Sevilla; Juan Manuel Malacara; Francisco J Gomez-Perez; Carlos A Aguilar-Salinas Journal: Eur J Endocrinol Date: 2010-06-01 Impact factor: 6.664
Authors: Estela M L Aquino; Maria Jenny Araujo; Maria da Conceição C Almeida; Patrícia Conceição; Célia Regina de Andrade; Nágela Valadão Cade; Marilia Sá Carvalho; Roberta Carvalho de Figueiredo; Maria de Jesus M da Fonseca; Luana Giatti; Greice Maria de Souza Menezes; Maria Angélica Nunes; Angelita Gomes de Souza; Paulo R Vasconcellos-Silva; Alvaro Vigo Journal: Rev Saude Publica Date: 2013-06 Impact factor: 2.106
Authors: Isabela M Bensenor; Rosane H Griep; Karina Araújo Pinto; Carolina Perim de Faria; Mariana Felisbino-Mendes; Edna I Caetano; Liliane da Silva Albuquerque; Maria Inês Schmidt Journal: Rev Saude Publica Date: 2013-06 Impact factor: 2.106
Authors: Joanna M N Guimarães; Rosane H Griep; Maria J M Fonseca; Bruce B Duncan; Maria I Schmidt; José G Mill; Paulo A Lotufo; Isabela J Bensenor; Sandhi M Barreto; Luana Giatti; Sheila M A Matos; Maria delC B Molina; Antonio G Pacheco; Dora Chor Journal: J Hum Hypertens Date: 2019-11-18 Impact factor: 3.012